Abstract: Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.

Abstract: The present invention concerns an anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea and its use in the treatment of cancer.

Abstract: The disclosure relates to the solubilization of docetaxel in an organic solvent, to the mixture thereof with polysorbate 80, and to the evaporation of the solvent.

Abstract: The present invention is a method of milling materials to form a fine powder with a median particle size below 10 micrometer which is suitable for inhalation and which has substantially no amorphous content generated during milling. The method is particularly suitable for milling materials which are soft. The method comprises milling the material in a fluid energy mill at reduced temperature using helium, or helium mixed with another gas, as milling fluid. Temperatures of ?30° C. or less are used.

Abstract: The present invention is a method of milling materials to form a fine powder with a median particle size below 10 micrometer which is suitable for inhalation and which has substantially no amorphous content generated during milling. The method is particularly suitable for milling materials which are soft. The method comprises milling the material in a fluid energy mill at reduced temperature using helium, or helium mixed with another gas, as milling fluid. Temperatures of ?30° C. or less are used.

Abstract: The invention is an improved method of generating fine medicament powders suitable for inhalation. A fluid energy mill is used with conventional milling fluids such as air or nitrogen. The milling fluid is treated to have a controlled relative humidity of between 30% and 70%. This produces a fine medicament powder with a median particle size below 10 micrometer but with little or no amorphous content generated during milling. Scale formation in the mill chamber is also greatly reduced.

Abstract: The present invention is a method of milling materials to form a fine powder with a median particle size below 10 micrometer which is suitable for inhalation and which has substantially no amorphous content generated during milling. The method is particularly suitable for milling materials which are soft. The method comprises milling the material in a fluid energy mill at reduced temperature using helium, or helium mixed with another gas, as milling fluid. Temperatures of −30° C. or less are used.

Abstract: The invention is an improved method of generating fine medicament powders suitable for inhalation. A fluid energy mill is used with conventional milling fluids such as air or nitrogen. The milling fluid is treated to have a controlled relative humidity of between 30% and 70%. This produces a fine medicament powder with a median particle size below 10 micrometer but with little or no amorphous content generated during milling. Scale formation in the mill chamber is also greatly reduced.

Abstract: The present invention is directed to 4,10.beta.-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1-hydroxy-9-oxo- 19-norcyclopropa(g)tax-11-en-13.alpha.-yl (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate dihydrate and a process for its preparation.

Abstract: Process for the preparation of 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta., 10.beta.-trihydroxy-9-oxo-tax-11-en-13.alpha.-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate trihydrate, characterized in that the 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,10.beta.-trihydro xy-9-oxo-tax-11-en-13.alpha.-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate is crystallized from a mixture of water and an aliphatic alcohol containing 1 to 3 carbon atoms, and then the product obtained is dried under defined conditions of temperature, pressure and humidity.

Abstract: A process for the preparation of 4,10-diacetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.-dihydroxy-9- oxo-tax-11-en-13.alpha.-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate trihydrate by crystallization from a water/alcohol solution.